Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN

GlobeNewswire August 22, 2019

Retrophin Reports Second Quarter 2019 Financial Results

GlobeNewswire August 6, 2019

Retrophin to Present at Canaccord Genuity's 39th Annual Growth Conference

GlobeNewswire July 31, 2019

Retrophin to Report Second Quarter 2019 Financial Results

GlobeNewswire July 23, 2019

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria

GlobeNewswire June 28, 2019

Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome

GlobeNewswire June 18, 2019

Retrophin to Present at Upcoming Investor Conferences

GlobeNewswire May 30, 2019

Retrophin Appoints Sandra E. Poole to Board of Directors

GlobeNewswire May 13, 2019

Retrophin Reports First Quarter 2019 Financial Results

GlobeNewswire May 7, 2019

Retrophin to Report First Quarter 2019 Financial Results

GlobeNewswire April 23, 2019

Retrophin to Present at Upcoming Investor Conferences

GlobeNewswire March 5, 2019

Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers

GlobeNewswire February 28, 2019

Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire February 26, 2019

Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 14, 2019

Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire February 12, 2019

Retrophin Provides Corporate Update and 2019 Outlook

GlobeNewswire January 7, 2019

The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

Benzinga.com  January 4, 2019

Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer

GlobeNewswire January 3, 2019

Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2019

Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy

GlobeNewswire December 27, 2018